Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
Primary Purpose
Amphetamine-Related Disorders
Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Bupropion
Sponsored by
About this trial
This is an interventional diagnostic trial for Amphetamine-Related Disorders
Eligibility Criteria
Inclusion Criteria: Please contact site director for more details. Exclusion Criteria: Please contact site director for more details.
Sites / Locations
- UCLA Integrated Substance Abuse Program
- University of Texas Health Science Center
Outcomes
Primary Outcome Measures
Psychological effects
BP, HR
Secondary Outcome Measures
Full Information
NCT ID
NCT00040040
First Posted
June 18, 2002
Last Updated
January 10, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of California, Los Angeles
1. Study Identification
Unique Protocol Identification Number
NCT00040040
Brief Title
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
Official Title
Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion
Study Type
Interventional
2. Study Status
Record Verification Date
August 2003
Overall Recruitment Status
Unknown status
Study Start Date
June 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
September 2003 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
University of California, Los Angeles
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.
Detailed Description
This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amphetamine-Related Disorders
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 1
Masking
Double
Allocation
Randomized
Enrollment
20 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Bupropion
Primary Outcome Measure Information:
Title
Psychological effects
Title
BP, HR
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Please contact site director for more details.
Exclusion Criteria:
Please contact site director for more details.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Newton, M.D.
Organizational Affiliation
National Institute on Drug Abuse (NIDA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA Integrated Substance Abuse Program
City
Los Angeles
State/Province
California
ZIP/Postal Code
90024
Country
United States
Facility Name
University of Texas Health Science Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77225
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1
We'll reach out to this number within 24 hrs